Biogen and Alcyone Therapeutics Announce License and Collaboration Agreement To Evaluate a Novel Device To Improve Patient Experience and Access to Neurological Aso Therapies

Biogen Inc. and Alcyone Therapeutics have entered into a license and collaboration agreement to develop Alcyone’s ThecaFlex DRxTM  System, an implantable medical device intended for subcutaneous delivery of antisense oligonucleotide (ASO) therapies into the intrathecal space. Through this agreement, Biogen aims to leverage the ThecaFlex DRxTM System with a goal of improving the patient treatment experience and accessibility for a broader population of people suffering from neurological disorders, such as spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS).

CROs dMed and Clinipace Merge To Accelerate Customer Success

dMed Global, a full-service Clinical Contract Research Organization (CRO) based in Shanghai, China, and UF startup Clinipace Incorporated, a full-service clinical CRO with headquarters in North Carolina, USA, announced that the two companies will merge.

Dialectic Therapeutics Receives FDA Clearance of IND Application for for Its Lead Product Candidate To Treat Cancer

UF startup Dialectic Therapeutics, Inc., a Texas-based biotechnology company focused on creating innovative new technologies to treat cancer, announced that the U.S. Food and Drug Administration (FDA) has concluded that Dialectic may proceed with its clinical investigation for its lead product candidate, DT2216, a unique compound built using its proprietary and novel Antiapoptotic Protein Targeted Degradation (APTaD) technology.